Sotrastaurin, a novel small molecule inhibiting protein-kinase C: Randomized phase II study in renal transplant recipients

American Journal of Transplantation

Volumn 11, Issue 7, 2011, Pages 1444-1455

  Friman, S ^a   Arns, W ^b   Nashan, B ^c   Vincenti, F ^d   Banas, B ^e   Budde, K ^f   Cibrik, D ^g   Chan, L ^h   Klempnauer, J ⁱ   Mulgaonkar, S ^j   Nicholson, M ^k   Wahlberg, J ^l   Wissing, K M ^m   Abrams, K ⁿ   Witte, S ⁿ   Woodle, E S ^o  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Kidney Transplant Service   (United States)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j SAINT BARNABAS MEDICAL CENTER   (United States)

^k UNIVERSITY OF LEICESTER   (United Kingdom)

^l UPPSALA UNIVERSITY   (Sweden)

^m ERASME HOSPITAL   (Belgium)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

Allotransplantation; calcineurin inhibitor toxicity; drug development; efficacy; immunosuppression; mycophenolic acid; renal function; safety; T cell activation; tacrolimus

Indexed keywords

BASILIXIMAB; MYCOPHENOLIC ACID; SOTRASTAURIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DYSGEUSIA; DYSURIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INSOMNIA; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREMOR; URINARY TRACT INFECTION; VOMITING;

ADULT; CALCINEURIN; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROTEIN KINASE C; PYRROLES; QUINAZOLINES; TACROLIMUS;

EID: 79959832380     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03538.x     Document Type: Article

References (27)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383. (Pubitemid 38282293)
2. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729. (Pubitemid 39665325)
3. Vincenti F, Ramos E, Brattstrom C, et al,. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287. (Pubitemid 32507148)
4. Ekberg H, Grinyo J, Nashan B, et al,. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study. Am J Transplant 2007; 7: 560-570. (Pubitemid 46376436)
5. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296-303.
6. Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ,. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024-1033.
7. Pietruck F, Klempnauer J, Arns W, et al,. Efficacy and Safety of Everolimus (RAD) / Enteric-coated Mycophenolate Sodium (EC-MPS) after Calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: Final results of the ZEUS trial. Am J Transplant 2009; s2: 499.
8. Weir M, Mulgaonkar S, Pearson T, et al,. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the spare-the-nephron (STN) trial. Am J Transplant 2009; s2: 200.
9. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
10. Buchler M, Caillard S, Barbier S, et al,. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531. (Pubitemid 47561618)
11. Spitaler M, Cantrell DA,. Protein kinase C and beyond. Nat Immunol 2004; 5: 785-790. (Pubitemid 39172971)
12. Guo B, Su TT, Rawlings DJ,. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004; 16: 367-373. (Pubitemid 38595376)
13. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A,. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 2002; 416: 860-865. (Pubitemid 34453743)
14. Bauer B, Krumbock N, Ghaffari-Tabrizi N, et al,. T cell expressed PKCtheta demonstrates cell-type selective function. Eur J Immunol 2000; 30: 3645-3654. (Pubitemid 32005238)
15. Pfeifhofer C, Gruber T, Letschka T, et al,. Defective IgG2a/2b class switching in PKC alpha-/- mice. J Immunol 2006; 176: 6004-6011.
16. Wagner J, Evenou J-P, Zenke G, et al,. The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates (NHP) and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies. Transplantation 2006; 82 (Abstract 57): 86.
17. Bruns C, Pally C, Beerli C, et al,. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimus or FTY720. Transplantation 2006; 1 (Abstract 741): 316.
18. Bigaud M, Wieczorek G, Riesen S, et al,. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate (NHP) kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (CsA). Transplantation 2006; 1 (Abstract 546): 250.
19. Bigaud M, Wieczorek G, Preussing E, et al,. NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C (PKC) and early T-cell activation, prolongs non-human primates (NHP) kidney allograft survival when combined with everolimus (RAD), ERL080 (ERL) or FTY720 (FTY) without calcineurin inhibitor (CNI). Transplantation 2006; 1 (Abstract 550): 251-252.
20. Skvara H, Dawid M, Kleyn E, et al,. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008; 118: 3151-3159.
21. Budde K, Sommerer C, Becker T, et al,. Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal-transplant recipients. Am J Transplant 2010; 10: 571-581.
22. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM,. Methotrexate vs. ciclosporin in psoriasis: Effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121. (Pubitemid 350221914)
23. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
24. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS,. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
25. Slade A, Pfrunder A, Koelle EU, Seiberling M, Schmouder R,. NVP-AEB071 pharmacokinetics: Combination with mycophenolate mofetil (Cellcept) is safe and does not result in an interaction. Transplantation 2006; 1 (Abstract 2436): 866.
26. Srinivas TR, Meier-Kriesche HU,. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol 2008; 2: S101-S116.
27. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010: 535-546.